Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions

Background: Homozygosity for the C allele of the −1T>C single nucleotide polymorphism (SNP) of the CD40 gene (rs1883832) is associated with susceptibility to coronary heart disease (CHD), enhanced CD40 expression, and shedding. The disintegrin metalloprotease ADAM17 can cleave various cell surface proteins. This study investigates an association between ADAM17-mediated CD40 shedding and inflammation in CC genotype human endothelial cells. Methods: Human umbilical vein endothelial cells (HUVEC) carrying the CC genotype were stimulated with soluble CD40 ligand (sCD40L) or tumor necrosis factor-α (TNFα). Messenger RNA and protein expression were determined with standard methods. Levels of high sensitive c-reactive protein (hs-CRP), interleukin-6 (IL-6), and sCD40 in plasma samples from patients with CHD were assessed using ELISA. Results: ADAM17 surface abundance was elevated following stimulation with CD40L and TNFα just as its regulator iRhom2. Inhibition of ADAM17 prevented TNFα-induced sCD40 and soluble vascular cell adhesion molecule-1 release into the conditioned medium and reinforced CD40 surface abundance. Secondary to inhibition of ADAM17, stimulation with CD40L or TNFα upregulated monocyte chemoattractant protein-1 mRNA and protein. Levels of sCD40 and the inflammatory biomarkers hs-CRP and IL-6 were positively correlated in the plasma of patients with CHD. Conclusions: We provide a mechanism by which membrane-bound CD40 is shed from the endothelial cell surface by ADAM17, boosting sCD40 formation and limiting downstream CD40 signaling. Soluble CD40 may represent a robust biomarker for CHD, especially in conjunction with homozygosity for the C allele of the −1T>C SNP of the CD40 gene.

[1]  T. Münzel,et al.  Role of CD40(L)-TRAF signaling in inflammation and resolution—a double-edged sword , 2022, Frontiers in Pharmacology.

[2]  A. Shore,et al.  Soluble CD40 receptor is a biomarker of the burden of carotid artery atherosclerosis in subjects at high cardiovascular risk. , 2022, Atherosclerosis.

[3]  A. Shore,et al.  Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype , 2021, Journal of stroke.

[4]  E. Nuti,et al.  Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution , 2021, Molecules.

[5]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[6]  A. Ludwig,et al.  Differential Induction of the ADAM17 Regulators iRhom1 and 2 in Endothelial Cells , 2020, Frontiers in Cardiovascular Medicine.

[7]  C. Gleissner,et al.  Functional association of a CD40 gene single nucleotide polymorphism with the pathogenesis of coronary heart disease. , 2020, Cardiovascular research.

[8]  E. Lutgens rs1883832: a CD40 single nucleotide polymorphism for predicting coronary heart disease in humans. , 2019, Cardiovascular research.

[9]  Y. H. Lee,et al.  Association between CD40 polymorphisms and systemic lupus erythematosus and correlation between soluble CD40 and CD40 ligand levels in the disease: a meta-analysis , 2019, Lupus.

[10]  W. März,et al.  Association of soluble CD40L with short-term and long-term cardiovascular and all-cause mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. , 2019, Atherosclerosis.

[11]  A. Ludwig,et al.  Status update on iRhom and ADAM17: It's still complicated. , 2019, Biochimica et biophysica acta. Molecular cell research.

[12]  M. Lampinen,et al.  High Serum sCD40 and a Distinct Colonic T Cell Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis , 2018, Journal of Crohn's & colitis.

[13]  L. Ferrucci,et al.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.

[14]  S. Rose-John,et al.  The shedding protease ADAM17: Physiology and pathophysiology. , 2017, Biochimica et biophysica acta. Molecular cell research.

[15]  R. D. Rudic,et al.  Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[16]  C. Weber,et al.  Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Copetti,et al.  A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. , 2015, Atherosclerosis.

[18]  Ghada S. Hassan,et al.  CD154: the atherosclerotic risk factor in rheumatoid arthritis? , 2013, Arthritis Research & Therapy.

[19]  P. Esposito,et al.  CD40/SCD40 imbalance in hemodialysis patients. , 2011, Clinical biochemistry.

[20]  A. Zernecke,et al.  Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. , 2009, Blood.

[21]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[22]  A. Toporik,et al.  Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. , 2008, Molecular immunology.

[23]  Daniel Paris,et al.  Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. , 2008, Cytokine.

[24]  G. Wang,et al.  Cholesterol-Dependent and -Independent CD40 Internalization and Signaling Activation in Cardiovascular Endothelial Cells , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[25]  M. Fujimoto,et al.  Increased serum soluble CD40 levels in patients with systemic sclerosis. , 2007, The Journal of rheumatology.

[26]  M. Hecker,et al.  CD154/CD40-Mediated Expression of CD154 in Endothelial Cells: Consequences for Endothelial Cell–Monocyte Interaction , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[27]  C. Blobel,et al.  Stimulated Shedding of Vascular Cell Adhesion Molecule 1 (VCAM-1) Is Mediated by Tumor Necrosis Factor-α-converting Enzyme (ADAM 17)* , 2003, Journal of Biological Chemistry.

[28]  S. Nagata,et al.  Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. , 2003, The Journal of biological chemistry.

[29]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[30]  Erlinda Concepcion,et al.  A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. , 2002, Thyroid : official journal of the American Thyroid Association.

[31]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[32]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[33]  H. Waldmann,et al.  Regulation of CD40 function by its isoforms generated through alternative splicing. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[35]  C. Bode,et al.  Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[36]  WolfgangKübler,et al.  Circulating Vascular Cell Adhesion Molecule-1 Correlates With the Extent of Human Atherosclerosis in Contrast to Circulating Intercellular Adhesion Molecule-1, E-Selectin, P-Selectin, and Thrombomodulin , 1997 .

[37]  U. Sen,et al.  Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* , 2006, Journal of Biological Chemistry.

[38]  P. Ridker,et al.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. , 2001, Circulation.